A method of reducing the feeling of vaginal dryness is provided. The method includes a female user suffering from vaginal dryness administering a vaginal care composition to her vaginal introitus and, optionally, external vaginal tissues. The vaginal care composition can comprise an oil-in-water emulsion and a silicone wax having a melting temperature of from about 24° C. to about 50° C. The vaginal care composition can also comprise silicone particles. The vaginal care composition can have a viscosity of from about 20,000 cps to about 200,000 cps.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

The present invention relates to a composition for preventing or treating scars and a preparation method therefor. The composition, according to one aspect, comprises a pigment and silicone oil, and may be stably formulated into a formulation adequate for spreading on the skin, and may inhibit the formation of scars or reduce already existing scars by forming a membrane on the skin, and has an effect whereby scars may be concealed by the pigment stably dispersed in the composition.

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

##STR00001##

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

##STR00001##

The present invention provides a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmacologically acceptable salt thereof:

##STR00001##

wherein two R moieties each independently are a C.sub.1-3 alkyl group or are groups bonded to each other to form a C.sub.2-5 alkylene group; A is an optionally substituted C.sub.6-10 aryl group or an optionally substituted heteroaryl group; and R.sup.1, R.sup.2 and R.sup.3 each independently are an optionally substituted linear or branched C.sub.1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.

The present invention provides a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmacologically acceptable salt thereof:

##STR00001##

wherein two R moieties each independently are a C.sub.1-3 alkyl group or are groups bonded to each other to form a C.sub.2-5 alkylene group; A is an optionally substituted C.sub.6-10 aryl group or an optionally substituted heteroaryl group; and R.sup.1, R.sup.2 and R.sup.3 each independently are an optionally substituted linear or branched C.sub.1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.